BPC-157
Summary
BPC-157 is a synthetic gastric pentadecapeptide with an extensive rodent literature suggesting benefits for tendon, ligament, muscle, bone, and gastrointestinal healing. There are no published randomized human trials, so its efficacy and safety in people are unproven.
Mechanism
BPC-157 is a stable 15-amino-acid peptide derived from a sequence found in human gastric juice. In animal models it appears to act as an angiogenic modulator — interacting with VEGF expression and the FAK-paxillin pathway to promote endothelial cell migration and coordinated vessel formation during tissue repair — alongside cytoprotective effects on gastrointestinal mucosa. Proposed mechanisms remain incompletely characterized, and no human receptor or definitive pathway has been established.
Reported effects
Ratings are relative to peers in the same category, not absolute claims.
Studied dosing — research context
Animal studies used microgram-per-kilogram-range doses by oral, intraperitoneal, or local routes depending on the injury model. No published human trial has established a dose, route, or duration, so there is no research-backed human dosing to describe. This describes the state of the literature, not guidance.
Research context only. This is not a recommendation.
Safety
Animal toxicology studies report low toxicity, but there are no published controlled human safety data. Human use relies entirely on uncontrolled anecdote, which cannot establish a safety profile. The absence of clinical trials means side effects, interactions, and long-term risks are unknown.
Limitations
The evidence base is overwhelmingly preclinical, and the large majority of it comes from a single research group, raising publication-bias concerns. A 2025 narrative review concluded that until well-designed clinical trials are conducted, BPC-157 should be considered unproven for musculoskeletal healing. There is no established human dose, route, or safety profile.